These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 31998325)

  • 1. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
    Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
    Front Immunol; 2019; 10():3069. PubMed ID: 31998325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.
    Podestà MA; Ruggiero B; Remuzzi G; Ruggenenti P
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31980477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.
    Seitz-Polski B; Dahan K; Debiec H; Rousseau A; Andreani M; Zaghrini C; Ticchioni M; Rosenthal A; Benzaken S; Bernard G; Lambeau G; Ronco P; Esnault VLM
    Clin J Am Soc Nephrol; 2019 Aug; 14(8):1173-1182. PubMed ID: 31340979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of PLA
    Schmidt T; Schulze M; Harendza S; Hoxha E
    J Nephrol; 2021 Apr; 34(2):603-606. PubMed ID: 33026632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update membranous nephropathy].
    Hoxha E; Huber TB
    Dtsch Med Wochenschr; 2020 Oct; 145(20):1481-1485. PubMed ID: 33022730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
    Seitz-Polski B; Payré C; Ambrosetti D; Albano L; Cassuto-Viguier E; Berguignat M; Jeribi A; Thouret MC; Bernard G; Benzaken S; Lambeau G; Esnault VL
    Nephrol Dial Transplant; 2014 Dec; 29(12):2334-42. PubMed ID: 25063424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre- and Posttransplant Refractory Idiopathic Membranous Glomerulonephritis: The Forgotten Potential Culprit.
    Barbari A
    Exp Clin Transplant; 2017 Oct; 15(5):483-489. PubMed ID: 28847264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial.
    Brglez V; Boyer-Suavet S; Zorzi K; Fernandez C; Fontas E; Esnault V; Seitz-Polski B
    Front Med (Lausanne); 2020; 7():412. PubMed ID: 32903623
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunohistochemical and serological characterization of membranous nephropathy in children and adolescents.
    Dettmar AK; Wiech T; Kemper MJ; Soave A; Rink M; Oh J; Stahl RAK; Hoxha E;
    Pediatr Nephrol; 2018 Mar; 33(3):463-472. PubMed ID: 29034405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
    Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
    Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.
    Conversano E; Debiec H; Colucci M; Emma F; Ronco P; Vivarelli M
    Pediatr Nephrol; 2024 Jan; 39(1):305-308. PubMed ID: 37466865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of membranous nephropathy: time for a paradigm shift.
    Ruggenenti P; Fervenza FC; Remuzzi G
    Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
    Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.